Carephar Pharmaceutical

Carephar Pharmaceutical is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-unmet-need areas, particularly metabolic diseases like gout and various oncology indications. Its lead program, CP-012, is a potent URAT1 inhibitor designed to treat hyperuricemia and has progressed into Phase 3 clinical trials. Carephar leverages its internal R&D platform to build a diverse pipeline of candidates targeting solid tumors and autoimmune disorders. The company has established strategic partnerships with major domestic pharmaceutical firms to accelerate the commercialization of its assets. Carephar is committed to delivering high-quality, affordable innovative medicines to patients worldwide.